-+ 0.00%
-+ 0.00%
-+ 0.00%

CMB International: The pharmaceutical industry's valuation repair market is expected to continue recommending targets such as Pharmaceutical and Biotech (02269)

Zhitongcaijing·11/17/2026 03:33:06
Listen to the news

The Zhitong Finance App learned that CMB International released a research report saying that the MSCI China Healthcare Index has accumulated a cumulative increase of 14.8% since the beginning of the year, outperforming the MSCI China Index by 32%. As the scale of BD transactions for innovative drugs overseas grows rapidly, the value of innovative pharmaceuticals going overseas depends on future milestone payments and sales shares. As the value of authorized varieties is realized, the valuations of related companies have a lot of room to rise, and targets such as Yao Ming Biotech (02269) and Yingen Bio-B (09606) are recommended.

The bank said that CXO also ushered in a boom in demand, and global CXO companies generally raised their annual revenue guidelines in the second and third quarters. The bank believes that CXO companies have high growth certainty, and that strong order growth and price increases will continue to drive performance until next year. Considering the strong implementation of innovative drugs and CXO fundamentals, the pharmaceutical industry's valuation repair market is expected to continue.